Education
About Us
Working with TipRanks
Follow Us
Indegene Limited (IN:INDGN)
:INDGN
INDGN Stock Chart & Stats
₹522.25
₹9.00(1.45%)
At close: 4:00 PM EST
₹522.25
₹9.00(1.45%)
Day’s Range― - ―
52-Week Range₹428.00 - ₹632.10
Previous CloseN/A
Volume943.30K
Average Volume (3M)17.62K
Market Cap
₹103.18B
Enterprise Value₹101.58B
Total Cash (Recent Filing)₹12.68B
Total Debt (Recent Filing)₹2.10B
Price to Earnings (P/E)30.3
Beta0.50
Next Earnings
Jun 03, 2026EPS Estimate
4.7Next Dividend Ex-DateN/A
Dividend Yield0.38%
Share Statistics
EPS (TTM)4.30
Shares Outstanding240,480,090
10 Day Avg. Volume12,460
30 Day Avg. Volume17,622
Financial Highlights & Ratios
PEG Ratio1.56
Price to Book (P/B)5.26
Price to Sales (P/S)4.85
P/FCF Ratio33.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹550.00Price Target Upside5.31% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)19.01
Revenue Forecast (FY)₹34.45B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthIndegene's sustained double-digit revenue growth through 2021–2025 signals durable market penetration of its tech-enabled services across life sciences clients. This supports longer-term top-line expansion driven by cross-selling, repeat engagements and multi-year contracts, reinforcing revenue predictability.
Margin SustainabilityConsistently high gross and operating margins reflect efficient delivery of regulated, high-value commercial and medical services plus scalable platform economics. Margin resilience supports durable profitability as scale increases, enabling reinvestment in technology and client solutions without eroding core returns.
Balance Sheet StrengthA substantial equity base and low leverage give Indegene financial flexibility to fund organic growth, platform development, or selective M&A. Reduced total debt and rising assets lower refinancing risk and support capital allocation choices that sustain long-term strategy through industry cycles.
Bears Say
EBITDA VolatilityThe abrupt EBITDA decline in 2025 points to persistent margin pressure risks—from client mix changes, pricing, or higher fixed costs—that could materially weaken cash generation. If structural, this would reduce funds available for reinvestment and slow medium-term growth and profitability recovery.
Cash Flow InconsistencyIrregular free cash flow growth and swings in investing/financing cash flows reduce predictability of internal funding for platforms, capex or acquisitions. Over time, this undermines strategic flexibility and may force higher external financing or delayed investments during adverse conditions.
Balance Sheet VariabilityObserved fluctuations in liabilities and equity hint at working-capital swings, client receivable timing or accounting variability. Persistent balance-sheet instability can constrain credit access, complicate long-range planning and increase effective financing costs, raising operational risk over months.
Indegene Limited News
INDGN FAQ
What was Indegene Limited’s price range in the past 12 months?
Indegene Limited lowest stock price was ₹428.00 and its highest was ₹632.10 in the past 12 months.
What is Indegene Limited’s market cap?
Indegene Limited’s market cap is ₹103.18B.
When is Indegene Limited’s upcoming earnings report date?
Indegene Limited’s upcoming earnings report date is Jun 03, 2026 which is in 79 days.
How were Indegene Limited’s earnings last quarter?
Indegene Limited released its earnings results on Jan 29, 2026. The company reported ₹4.3 earnings per share for the quarter, missing the consensus estimate of ₹5.15 by -₹0.85.
Is Indegene Limited overvalued?
According to Wall Street analysts Indegene Limited’s price is currently Undervalued.
Does Indegene Limited pay dividends?
Indegene Limited pays a Notavailable dividend of ₹2 which represents an annual dividend yield of 0.38%. See more information on Indegene Limited dividends here
What is Indegene Limited’s EPS estimate?
Indegene Limited’s EPS estimate is 4.7.
How many shares outstanding does Indegene Limited have?
Indegene Limited has 240,480,090 shares outstanding.
What happened to Indegene Limited’s price movement after its last earnings report?
Indegene Limited reported an EPS of ₹4.3 in its last earnings report, missing expectations of ₹5.15. Following the earnings report the stock price went down -1.262%.
Which hedge fund is a major shareholder of Indegene Limited?
Currently, no hedge funds are holding shares in IN:INDGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Indegene Limited
Indegene Limited operates as a life sciences commercialization company in India and internationally. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get to the market, and grow impact through the life cycle. The company offers enterprise commercial solutions, enterprise medical solutions, enterprise clinical solutions, omnichannel activation solutions, and NEXT technology platforms. The company was incorporated in 1998 and is based in Bengaluru, India.
INDGN Stock 12 Month Forecast
Average Price Target
₹550.00
▲(5.31% Upside)
Technical Analysis
ITI Limited
―
KPIT Technologies Limited
―
Mphasis Limited
―
Tata Elxsi Limited
―
Tech Mahindra Limited
―